Novavax to Report First Quarter 2011 Financial Results on May 9, 2011

ROCKVILLE, Md., May 3, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) will report financial results for the first quarter of 2011 on Monday, May 9, 2011, before the U.S. financial markets open.  The announcement will be followed by a webcast and conference call hosted by Stanley C. Erck, President and Chief Executive Officer, and other members of senior management at 10:00 a.m. Eastern time.

The webcast and conference call will be available at www.novavax.com under Investors/Events.  The dial-in number for the conference call is 1-877-212-6076 (domestic) or 1-707-287-9331 (international).  Webcast and telephone replays of the conference call will be available shortly after the completion of the call.  To access the replay, dial 1-800-642-1687 (domestic) or 1-706-645-9291 (international) and use passcode 63923693.

About Novavax

Novavax, Inc. (Nasdaq: NVAX), a clinical-stage biopharmaceutical company, employs its cutting-edge technology to create next-generation vaccines to prevent serious infectious diseases, such as pandemic and seasonal influenza and respiratory syncytial virus (RSV).  The company's proprietary virus-like-particle (VLP) technology and single-use bioprocessing system enable rapid vaccine development and production where and when they are needed, worldwide.  The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India.  Additional information about Novavax is available on the company's website: www.novavax.com.

SOURCE Novavax, Inc.

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.